ArticleCureus2026
Spontaneous Regression of Soft Tissue Sarcoma Following Biopsy: A Case Report and Systematic Review of the Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spontaneous regression (SR) of malignancy is a rare phenomenon offering unique insights into tumor-host immunology. In sarcomas, the incidence, triggers, and clinical implications of SR are poorly characterized. We aim to synthesize the published literature on SR in sarcoma and report a novel case from our institution where diagnostic biopsy triggered a complete pathological response (pCR). We retrospectively reviewed one institutional case: a 59-year-old female with myxofibrosarcoma (MFS) who demonstrated significant regression following core needle biopsy. We subsequently conducted a descriptive systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, rather than a formal meta-analysis. PubMed, Embase, and Scopus were searched from inception to July 2025 for reports of SR in pathologically confirmed sarcomas without prior cytotoxic therapy. In our institutional experience, the patient (59-year-old female, MFS) achieved complete clinical resolution within weeks of biopsy. Definitive wide excision revealed no viable tumor cells, confirming pCR. The systematic review identified 32 published studies describing 32 unique cases of SR in sarcoma. Diagnostic biopsy was the leading identified trigger (25%). Biopsy-associated regressions occurred more rapidly (median 0.9 months) compared to infection-associated (median five months) or spontaneous cases. Despite clinical regression, 75% of patients in the biopsy-triggered group underwent definitive surgical resection. SR in sarcoma is frequently preceded by an immune-stimulating event, most notably biopsy. While SR provides in vivo evidence of host anti-tumor immunity, the potential for incomplete or transient response underscores that SR should not preclude definitive oncologic management. Ultimately, SR can be conceptualized as a "neoadjuvant immune boost" rather than a definitive cure. Wide surgical resection based on pre-regression tumor fields remains the standard of care to eradicate microscopic disease and ensure oncologic safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.